Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379702 | 0.86 | GDA (0.34) | PDPK1GDAPNPTYMSKDM4E | |
| SCHEMBL14260671 | 0.82 | GDA (0.39) | GDAPNPXDHACHEKDM4E | |
| SCHEMBL27496340 | 0.81 | GDA (0.36) | PDPK1GDAPNPXDHPARP1 | |
| SCHEMBL10047094 | 0.81 | XDH (0.40) | PDPK1GDAPNPXDHACHE | |
| SCHEMBL5062459 | 0.81 | XDH (0.46) | GDAPNPXDHKDM4EALDH1A1 | |
| SCHEMBL5021600 | 0.81 | PIM1 (0.38) | PDPK1GDAPNPXDHPARP1 | |
| SCHEMBL219477 | 0.80 | GDA (0.62) | GDAPNPKDM4EALDH1A1LMNA | |
| SCHEMBL9020532 | 0.79 | TYMS (0.39) | PDPK1GDAPNPTYMSXDH | |
| SCHEMBL26174316 | 0.79 | XDH (0.53) | GDAPNPXDHKDM4EALDH1A1 | |
| SCHEMBL17373199 | 0.79 | CSNK2A2 (0.37) | PDPK1CSNK2A2CSNK2BCSNK2A1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2828 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025038970-A1 | MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-8188254-B2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| CN-101454451-A | Class C oligonucleotide analogs with enhanced immunostimulatory capacity | COLEY PHARM GMBH (DE) | 2009-06-10 | — | — | CN | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| EP-1678303-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical GmbH (DE) | 2006-07-12 | — | — | EP | claimed |
| US-20050239734-A1 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1578954-A2 | 5' CPG NUCLEIC ACIDS AND METHODS OF USE | Coley Pharmaceutical Group, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005042018-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20040171571-A1 | 5' CpG nucleic acids and methods of use | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-09-02 | — | — | US | claimed |
| WO-2004053104-A2 | 5’ CPG NUCLEIC ACIDS AND METHODS OF USE | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | claimed |